Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer

Carcinogenesis

Volumn 27, Issue 10, 2006, Pages 2133-2139

  Goodlad, R A ^a,c   Ryan, A J ^b   Wedge, S R ^b   Pyrah, I T ^b   Alferez, D ^a,c   Poulsom, R ^a   Smith, N R ^b   Mandir, N ^a   Watkins, A J ^a   Wilkinson, R W ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; BETA CATENIN; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL COUNT; COLON POLYP; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; EARLY CANCER; EARLY INTERVENTION; FEMALE; INTESTINE CANCER; INTESTINE POLYP; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SMALL INTESTINE; TUMOR GROWTH; TUMOR VOLUME;

ADENOMA; ANIMALS; FEMALE; GENES, APC; INTESTINAL NEOPLASMS; INTESTINAL POLYPS; MALE; MICE; MICE, INBRED C57BL; QUINAZOLINES; RNA, MESSENGER; SIGNAL TRANSDUCTION; SPLENOMEGALY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33749549907     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl113     Document Type: Article

References (38)

1. Weitz,J., Koch,M., Debus,J., Hohler,T., Galle,P.R. and Buchler,M.W. (2005) Colorectal cancer. Lancet, 365, 153-165.
2. Fearon,E.R. and Vogelstein,B. (1990) A genetic model for colorectal tumorigenesis. Cell, 61, 759-767.
3. Ilyas,M., Straub,J., Tomlinson,I.P. and Bodmer,W.F. (1999) Genetic pathways in colorectal and other cancers. Eur. J. Cancer, 35, 335-351.
4. Polakis,P. (2000) Wnt signaling and cancer. Genes Dev., 14, 1837-1851.
5. Moser,A.R., Pitot,H.C. and Dove,W.F. (1990) A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science, 247, 322-324.
6. Novelli,M.R., Preston,S.I., Kyriakes,E., Oukrif,D., Tomlinson,I.P., Poulson,R. and Wright,N.A. (2003) Intra-villous adenomas in the duodenum of patients with FAP: Implications for the origins of adenomas and for the relevance of mouse models for intestinal neoplasia. Gastroenterology, 124, A-132.
7. Corpet,D.E. and Pierre,F. (2003) Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol. Biomarkers Prev., 12, 391-400.
8. Boivin,G.P., Washington,K., Yang,K. et al. (2003) Pathology of mouse models of intestinal cancer: Consensus report and recommendations. Gastroenterology, 124, 762-777.
9. Hanahan,D. and Weinberg,R.A. (2000) The hallmarks of cancer. Cell, 100, 57-70.
10. Hanahan,D. and Folkman,J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353-364.
11. Leung,D.W., Cachianes,G., Kuang,W.J., Goeddel,D.V. and Ferrara,N. (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 246, 1306-1309.
12. Lu,D., Kussie,P., Pytowski,B., Persaud,K., Bohlen,P., Witte,L. and Zhu,Z. (2000) Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies. J. Biol. Chem., 275, 14321-14330.
13. Tammela,T., Enholm,B., Alitalo,K. and Paavonen,K. (2005) The biology of vascular endothelial growth factors. Cardiovasc. Res., 65, 550-563.
14. Hicklin,D.J. and Ellis,L.M. (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol., 23, 1011-1027.
15. Wedge,S.R., Kendrew,J., Hennequin,L.F. et al. (2005) AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res., 65, 4389-4400.
16. Dietrich,W.F., Lander,E.S., Smith,J.S., Moser,A.R., Gould,K.A., Luongo,C., Borenstein,N. and Dove,W. (1993) Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell, 75, 631-639.
17. Bashir,O., Fitzgerald,A.J. and Goodlad,R.A. (2004) Both suboptimal and elevated vitamin intake increase intestinal neoplasia and alter crypt fission in the ApcMin/+ mouse. Carcinogenesis, 25, 1507-1515.
18. Bashir,O., Fitzgerald,A.J., Berlanga-Acosta,J., Playford,R.J. and Goodlad,R.A. (2003) Effect of epidermal growth factor administration on intestinal cell proliferation, crypt fission and polyp formation in multiple intestinal neoplasia (Min) mice. Clin. Sci. (Lond.), 105, 323-330.
19. Kongkanuntn,R., Bubb,V.J., Sansom,O.J., Wyllie,A.H., Harrison,D.J. and Clarke,A.R. (1999) Dysregulated expression of beta-catenin marks early neoplastic change in Apc mutant mice, but not all lesions arising in Msh2 deficient mice. Oncogene, 18, 7219-7225.
20. Goodlad,R.A., Madgwick,A.J., Moffatt,M.R., Levin,S., Allen,J.L. and Wright,N.A. (1990) Prostaglandins and the dog stomach: Effects of misoprostol on the proportion of mucosa to muscle and on the proportion of different epithelial cell types. Digestion, 45, 212-216.
21. Aherne,W.A. and Dunhill,M. (1982) Morphometry. Edward Arnold, London.
22. Senior,P.V., Critchley,D.R., Beck,F., Walker,R.A. and Varley,J.M. (1988) The localization of laminin mRNA and protein in the postimplantation embryo and placenta of the mouse: An in situ hybridization and immunocytochemical study. Development, 104, 431-446.
23. Poulsom,R., Longcroft,J.M., Jeffery,R.E., Rogers,L.A. and Steel,J.H. (1998) A robust method for isotopic riboprobe in situ hybridisation to localise mRNAs in routine pathology specimens. Eur. J. Histochem., 42, 121-132.
24. Orner,G.A., Dashwood,W.M., Blum,C.A., Diaz,G.D., Li,Q., Al Fageeh,M., Tebbutt,N., Heath,J.K., Ernst,M. and Dashwood,R.H. (2002) Response of Apc(min) and A33 (delta N beta-cat) mutant mice to treatment with tea, sulindac, and 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP). Mutat. Res., 506-507, 121-127.
25. Peterson,J.K. and Houghton,P.J. (2004) Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur. J. Cancer, 40, 837-844.
26. Jonkers,J. and Berns,A. (2002) Conditional mouse models of sporadic cancer. Nat. Rev. Cancer, 2, 251-265.
27. Paulsen,J.E. (2000) Modulation by dietary factors in murine FAP models. Toxicol. Lett., 112-113, 403-409.
28. Bergers,G. and Benjamin,L.E. (2003) Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer, 3, 401-410.
29. Gunsilius,E., Tschmelitsch,J., Eberwein,M., Schwelberger,H., Spizzo,G., Kahler,C.M., Stockhammer,G., Lang,A., Petzer,A.L. and Gastl,G. (2002) In vivo release of vascular endothelial growth factor from colorectal carcinomas. Oncology, 62, 313-317.
30. Hanrahan,V., Currie,M.J., Gunningham,S.P., Morrin,H.R., Scott,P.A., Robinson,B.A. and Fox,S.B. (2003) The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J. Pathol., 200, 183-194.
31. Gutierrez,L.S., Suckow,M., Lawler,J., Ploplis,V.A. and Castellino,F.J. (2003) Thrombospondin 1 - a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model. Carcinogenesis, 24, 199-207.
32. Oshima,M., Murai,N., Kargman,S., Arguello,M., Luk,P., Kwong,E., Taketo,M.M. and Evans,J.F. (2001) Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res., 61, 1733-1740.
33. Seno,H., Oshima,M., Ishikawa,T.O., Oshima,H., Takaku,K., Chiba,T., Narumiya,S. and Taketo,M.M. (2002) Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res., 62, 506-511.
34. Wali,R.K., Roy,H.K., Kim,Y.L., Liu,Y., Koetsier,J.L., Kunte,D.P., Goldberg,M.J., Turzhitsky,V. and Backman,V. (2005) Increased microvascular blood content is an early event in colon carcinogenesis. Gut, 54, 654-660.
35. Hlatky,L., Hahnfeldt,P. and Folkman,J. (2002) Clinical application of antiangiogenic therapy: Microvessel density, what it does and doesn't tell us. J. Natl Cancer Inst., 94, 883-893.
36. Easwaran,V., Lee,S.H., Inge,L. et al. (2003) Beta-catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res., 63, 3145-3153.
37. Inai,T., Mancuso,M., Hashizume,H. et al. (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol., 165, 35-52.
38. Baffert,F., Thurston,G., Rochon-Duck,M., Le,T., Brekken,R. and McDonald,D.M. (2004) Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. Circ. Res., 94, 984-992.